Edition:
United Kingdom

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

0.58USD
22 Mar 2019
Change (% chg)

$-0.04 (-6.65%)
Prev Close
$0.62
Open
$0.62
Day's High
$0.62
Day's Low
$0.57
Volume
426,460
Avg. Vol
533,523
52-wk High
$3.58
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Aveo Reports Full Year 2018 Financial Results And Provides Business Update
Thursday, 14 Mar 2019 

March 14 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.AVEO PHARMACEUTICALS INC QTRLY DILUTED LOSS PER SHARE $0.03.AVEO PHARMACEUTICALS INC QTRLY BASIC EARNINGS PER SHARE $0.18.AVEO PHARMACEUTICALS INC QTRLY REVENUES $1,483,000 VERSUS $82,000.  Full Article

Aveo Says Accepted Recommendation Of FDA To Not Submit Marketing Application For Tivozanib
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO ONCOLOGY ANNOUNCES NDA TIMING UPDATE.AVEO PHARMACEUTICALS- ACCEPTED RECOMMENDATION OF FDA NOT TO SUBMIT NDA FOR TIVOZANIB WITH PRELIMINARY OVERALL SURVIVAL RESULTS FROM PHASE 3 TIVO-3 TRIAL.AVEO PHARMACEUTICALS INC - CO NOW PLANS TO MAKE A NDA FILING DECISION FOLLOWING AVAILABILITY OF MORE MATURE OS RESULTS FOR TIVOZANIB.  Full Article

Aveo Oncology Collaborates With Astrazeneca
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO ONCOLOGY ANNOUNCES IMMUNO-ONCOLOGY CLINICAL COLLABORATION WITH ASTRAZENECA.AVEO PHARMACEUTICALS INC - PHASE 1/2 STUDY WILL EVALUATE COMBINATION OF IMFINZI (DURVALUMAB) AND FOTIVDA (TIVOZANIB) IN FIRST-LINE HCC.AVEO PHARMACEUTICALS INC - AVEO WILL SERVE AS STUDY SPONSOR, WITH STUDY COSTS SHARED EQUALLY BY BOTH PARTIES.AVEO PHARMACEUTICALS INC - CLINICAL DRUG WILL BE SUPPLIED BY EACH RESPECTIVE COMPANY.AVEO PHARMACEUTICALS INC - PHASE 1 PORTION OF STUDY IS EXPECTED TO COMMENCE IN 2019..  Full Article

Aveo oncology announces extension of debt facility interest only period
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO ONCOLOGY ANNOUNCES EXTENSION OF DEBT FACILITY INTEREST ONLY PERIOD.AVEO PHARMACEUTICALS - ANNOUNCED 6 MONTH EXTENSION TO INTEREST ONLY PERIOD UNDER EXISTING AMENDED & RESTATED LOAN & SECURITY AGREEMENT WITH HERCULES CAPITAL.AVEO PHARMACEUTICALS - COMPANY WILL BEGIN MAKING PRINCIPAL PAYMENTS ON $20.0 MILLION FACILITY STARTING ON AUGUST 1, 2019.AVEO PHARMACEUTICALS INC - EXTENDS CASH RUNWAY TO FUND PLANNED OPERATIONS INTO Q3 OF 2019.  Full Article

Aveo Reports Second Quarter 2018 Financial Results
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.06.Q2 REVENUE $400,000 VERSUS $400,000.Q2 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S.  Full Article

Aveo Oncology Says Expects To Report Topline Results From Tivo-3 Study In Q4 Of 2018
Thursday, 19 Jul 2018 

July 19 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO ONCOLOGY ISSUES STATEMENT REGARDING REVISED TIVO-3 TRIAL GUIDANCE.AVEO PHARMACEUTICALS INC - EXPECTS TO REPORT TOPLINE RESULTS FROM TIVO-3 STUDY IN Q4 OF 2018.AVEO PHARMA - REVISED GUIDANCE DUE TO PFS EVENTS OCCURRING SLOWER THAN FORECASTED, 10 PATIENTS BEING REMOVED OR 'CENSORED' FROM PFS EVENT COUNT.AVEO PHARMA - ADJUSTMENT IN PFS EVENT COUNT DUE TO ERROR FROM COUNTING DEATHS OF 10 PATIENTS WHO LEFT STUDY WITHOUT DOCUMENTED RADIOGRAPHIC PROGRESSION.AVEO PHARMACEUTICALS INC - FOLLOWING ADJUSTMENT, AND AS OF JULY 18, PFS EVENT COUNT IS 243.AVEO PHARMACEUTICALS INC - ADMINISTRATIVE ERROR WAS DISCOVERED AS PART OF DATA CLEANING AND REVIEW PROCESS.AVEO PHARMACEUTICALS INC - PLANS TO ANNOUNCE WHEN 255 PFS EVENTS HAVE OCCURRED AND TOPLINE DATA ANALYSIS FOR TRIAL HAS BEEN INITIATED.  Full Article

Aveo Pharmaceuticals Says Entered Warrant Agreement With Computershare And Computershare Trust Company, N.A
Monday, 16 Jul 2018 

July 16 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS INC SAYS ENTERED WARRANT AGREEMENT WITH COMPUTERSHARE INC. AND COMPUTERSHARE TRUST COMPANY, N.A. - SEC FILING.AVEO PHARMACEUTICALS - WARRANT AGREEMENT DESCRIBES TERMS OF WARRANTS FOR PURCHASE OF 2 MILLION SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE.AVEO PHARMACEUTICALS INC - WARRANTS ISSUED PURSUANT TO TERMS OF STIPULATION OF SETTLEMENT OF A SECURITIES CLASS ACTION LAWSUIT.AVEO PHARMACEUTICALS - CLAIMS AGAINST CO & INDIVIDUAL DEFENDANTS BY THE CLASS RELEASED FOR CONSIDERATION OF CASH PAYMENT OF $15 MILLION, SETTLEMENT WARRANTS.AVEO - CO NOW EXPECTS TO REPORT TIVO-3 TOPLINE DATA IN Q4 2018, DUE TO PROGRESSION-FREE SURVIVAL EVENTS OCCURRING SLOWER THAN FORECASTED.  Full Article

Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT.AVEO- UNDER MOU, AGREED FOR PLAINTIFFS TO CAUSE SOME OF CO'S, INDIVIDUAL DEFENDENTS' INSURANCE CARRIERS TO PROVIDE THE CLASS WITH $15 MILLION CASH PAYMENT.AVEO PHARMACEUTICALS SAYS ADDITIONALLY, CO AGREED TO ISSUE TO THE CLASS WARRANTS FOR PURCHASE OF 2 MILLION SHARES OF AVEO COMMON STOCK - SEC FILING.AVEO PHARMACEUTICALS - IN CONSIDERATION OF SETTLEMENT PAYMENT, PLAINTIFFS AGREED THAT SETTLEMENT WILL INCLUDE DISMISSAL OF CLASS ACTION WITH PREJUDICE.AVEO PHARMA - CONSIDERING SETTLEMENT PAYMENT, PLAINTIFFS AGREED SETTLEMENT WILL INCLUDE RELEASE OF ALL CLAIMS AGAINST CO, INDIVIDUAL DEFENDANTS BY THE CLASS.  Full Article

Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Aveo Pharmaceuticals Inc :AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.22.‍BELIEVE THAT OUR $37.4 MILLION IN CASH RESOURCES WOULD ALLOW US TO FUND OUR PLANNED OPERATIONS INTO Q4 OF 2018​.  Full Article

BRIEF-Aveo Pharmaceuticals Says Co Entered Agreement With Novartis International Pharmaceutical Regarding Aveo's AV380 Program

* AVEO PHARMACEUTICALS INC - ON DEC. 18, AVEO ENTERED AGREEMENT WITH NOVARTIS INTERNATIONAL PHARMACEUTICAL REGARDING AVEO’S AV380 PROGRAM